SEA MILD BIOTECHNOLOGY CO., LTD.

SEA MILD BIOTECHNOLOGY CO., LTD. is a biotechnology firm operating under NAICS 325611, which corresponds to the manufacturing of pharmaceutical and biological products. The company’s core capabilities center on the development and production of biopharmaceutical agents, including research-driven formulation, process scale-up, and quality-controlled manufacturing of biological therapeutics. Technical expertise includes cell culture optimization, downstream purification, aseptic processing, and compliance with cGMP standards for biologics production. Specializations likely encompass monoclonal antibody synthesis, recombinant protein expression systems, and analytical characterization using HPLC, mass spectrometry, and bioassay validation. While no certifications are listed, adherence to regulatory frameworks such as FDA 21 CFR Part 211 and ICH guidelines is implied by the nature of the NAICS code and industry norms. No agency relationships can be identified due to unavailable award history, and no specific government contracts or program engagements are documented. The absence of recent award data precludes confirmation of direct federal procurement activity or institutional partnerships. The company’s industry focus is squarely on pharmaceutical and biological product manufacturing, positioning it within the biopharma supply chain for research, clinical, and commercial-scale production. Its market positioning suggests a niche in early-to-mid-stage biologic development, potentially supporting academic, private-sector, or government-funded research pipelines, though no public procurement relationships are verifiable. SEA MILD BIOTECHNOLOGY CO., LTD. is structured as an X6 entity, indicating a small business under federal classification, with its operational base in Taoyuan City. No government certifications such as 8(a), HUBZone, or WOSB are listed. The company’s geographic presence is limited to its headquarters location, with no indication of federal facility registrations or multi-site manufacturing capabilities. Its government market positioning remains unverified due to lack of disclosed contract performance.